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New chapter in tackling antimicrobial resistance 
in Thailand
Nithima Sumpradit and colleagues describe the experience of Thailand in developing its 
national strategic plan on antimicrobial resistance and highlight the need for sustained political 
commitment and multisectoral collaboration
Key messages
•   Thailand has actively contributed to 
setting the global agenda on antimi-
crobial resistance
•   The national strategic plan on antimi-
crobial resistance (2017-21) promotes 
multisectoral collaboration to reduce 
antimicrobial consumption and AMR 
morbidity and improve public aware-
ness
•   Strengthening surveillance systems to 
measure the burden of AMR and the 
effect of policies must be a priority
A
ntimicrobial resistance (AMR) 
is   a  serious  global  health 
threat which can cross borders 
and   human   and   an ima l 
species. Concerted action is 
required at global, regional and national 
levels  to  tackle  it. The World Health 
Assembly adopted  the global action 
plan on AMR  in 2015, which  called 
on member states of the World Health 
Organization to develop national action 
plans by May 2017.1 To date, 67 member 
states  have  finalised  their  national 
action plans.
AMR places a high burden on health 
and the economy in Thailand,2 and the 
government has shown strong political 
commitment to tackle AMR over the past 
decade. Box 1 summarises the effect of 
AMR and antimicrobial consumption in 
Thailand.
Earlier  initiatives  to  tackle  AMR, 
summarised in box 2, have shown some 
success in reducing the inappropriate use 
of antimicrobials, but progress has been 
slow. A need was  felt  to  integrate and 
consolidate actions across different sectors 
and to monitor progress.
In   2016,   the   cabinet   endorsed 
the  first  five  year  National  Strategic 
Plan  on  Antimicrobial  Resistance  in 
Thailand for 2017 to 2021. The cabinet 
endorsement gives the plan legal status for 
implementation in different sectors. The 
plan is based on the One Health 6 approach 
and takes account of the key components 
and strategic objectives of the WHO global 
action plan on AMR.
Box 1: Burden and prevalence of antimicrobial resistance in Thailand2
AMR burden*
•  About 88 000 infections were attributed to antimicrobial resistance (AMR), resulting in at 
least 3.24 million additional days in hospital and 38 000 deaths
•  Direct costs of antibiotics to treat AMR infection were about $70-$170m (£54-£132m; €62-
€150m; 2400-5800m baht)
•  Indirect costs of morbidity and premature deaths related to AMR were at least $1100m
AMR prevalence†
•  Important resistant pathogens include imipenem resistant Acinetobacter spp, 
imipenem resistant Pseudomonas aeruginosa, vancomycin resistant enterococci, 
carbapenem resistant Enterobacteriaceae, extended spectrum β-lactamase 
producing Enterobacteriaceae, and multidrug resistant and extensive drug 
resistant tuberculosis
•  Between 2000 and 2014, the prevalence of imipenem resistant P aeruginosa and 
Acinetobacter spp increased from 10% to 22% and from 14% to 65%, respectively
Antimicrobial consumption‡
•  More than 5200 antimicrobial products are registered with the Thai Food and 
Drug Administration, of which two thirds are for humans and the remainder for 
animals
•  Antimicrobials account for 15-20% of the total human drug costs, and 50% of 
antimicrobial consumption is antibiotics; the other 50% are antiviral, antifungal, and 
other drugs 
•  $315m was spent on antibiotics in 2009, which is higher than on medicines for 
cardiovascular diseases ($260m) and cancer ($225m)
•  Penicillins, cephalosporins and carbapenems are the top three antibiotics consumed.
*Based on data from 2010 for five bacteria: Escherichia coli, Klebsiella pneumoniae, A. baumannii, P aeruginosa and meticillin 
resistant Staphylococcus aureus.
†AMR prevalence is based on data from the National Antimicrobial Resistance Surveillance Center, Ministry of Public Health 
‡Antimicrobial consumption is estimated from the consumption value as a proxy measure. The drug consumption value 
is the sum of the drug production and importation values reported by drug companies to the FDA annually. The Thai 
Surveillance of Antimicrobial Consumption System (Thai SAC), which is under development, will monitor antimicrobial 
consumption for humans as the defined daily dose per 1000 inhabitants per day, guided by WHO methods,3 and for animals 
as the mg per population correction unit, as used by the European Surveillance of Veterinary Antimicrobial Consumption 
project.4 
Box 2: Initiatives on AMR in Thailand
•  National AMR Surveillance Centre was established in 1998 at the Ministry of Public Health 
and has been a WHO Collaborating Centre for AMR Surveillance for the South-East Asia region 
since 2005
•  The nosocomial infection control programme was started in 1971
•  Antibiotics Smart Use Program was started in 2007; it aims to reduce unnecessary 
prescriptions of antibiotics for common self-limiting conditions, including upper 
respiratory tract infections, acute diarrhoea, and simple wounds. Hospitals that achieve 
the approved standards for appropriate use of antibiotics for these conditions will 
receive financial rewards through the pay-for-performance policy of the National Health 
Security Office5
•  An antibiotic awareness day has been held annually since 2013 to create public awareness 
about AMR and the appropriate use of antibiotics
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Developing the national strategic plan on AMR
Understanding the landscape and complex 
nature of AMR
Understanding the complex setting and 
stakeholders was essential  to develop 
appropriate and feasible policies for Thai-
land to tackle AMR. Thailand has about 24 
committees, subcommittees, and working 
groups related to AMR, almost all under the 
Ministry of Public Health, and the Ministry 
of Agriculture and Cooperatives.7 Other 
government organisations, professional 
associations on human and animal health, 
the private sector, and civil society organi-
sations are also involved. However, there 
was no common platform for these groups 
to work together.
In October 2014, the Ministry of Public 
Health  held  a meeting with  all  these 
stakeholders to review past and ongoing 
initiatives and outline  the problem of 
AMR. The meeting had two key outcomes. 
First,  it  led  to  the  technical  report on 
AMR in Thailand.7 This report gave AMR 
stakeholders the overall background on 
AMR and the actions taken by various 
stakeholders.  It also  led  to a series of 
discussions  between  the  ministries 
of public health,  and agriculture and 
cooperatives, which established an AMR 
coordination and integration committee to 
develop the national strategic plan.7
Engaging stakeholders
In line with the principle of the global 
action plan on AMR to include all society,8 
action was taken at both the policy and 
public level to involve a wide group of 
stakeholders  to  move  the  AMR  plan 
forward.
At  the  public  level,  the  National 
Health Assembly, which brings together 
representatives  from  government, 
academia, private sector, and civil society 
from all 77 provinces of Thailand, passed 
a resolution on AMR. The representatives 
draft resolutions which are discussed at 
provincial forums held in each province. 
The  resolution  is  then  finalised  and 
adopted at the national assembly. While 
not  legally binding,  the participatory 
nature of the process gives it legitimacy, 
creates  public  awareness  and  helps 
implementation.9 In December 2015, the 
national health assembly resolution on 
AMR was adopted;  it  includes various 
actions  for  the  ministries  of  public 
health, agriculture and cooperatives and 
education, other governmental agencies, 
national and provincial health assemblies, 
local  government  units,  civil  society 
organisations, and the private sector.10
At the policy level, government staff 
and  key  stakeholders  facilitated  the 
development and implementation of the 
national  strategic plan.  In May 2015, 
the Ministry of Public Health appointed 
the AMR coordination and integration 
committee to develop the strategic plan. 
The committee held a workshop with more 
than 120 key stakeholders from all sectors 
to get their input. After several rounds of 
meetings, and public and stakeholder 
consultations, the plan was finalised and 
endorsed by the cabinet in August 2016.
Joining forces with regional and global 
stakeholders
Thailand has made several contributions to 
tackle AMR at the regional and global level 
(box 3). The contribution by Thailand to the 
global agenda on AMR (“inside out”) and 
the contribution of the global community to 
Thailand’s affirmative actions (“outside in”) 
have together created a momentum that has 
strengthened and sustained national com-
mitment.
Translating the national plan into action
The national plan on AMR is intended to 
facilitate multisectoral action and achieve 
measureable outcomes. Figure 1 shows the 
roles and contributions of different stake-
holders. Implementation and evaluation 
have been planned jointly to monitor pro-
gress and ensure accountability.
Programme implementation
The plan (box 4) sets out five goals to be 
achieved by 2021 which focus on reducing 
AMR morbidity in hospitals and antimicro-
bial consumption in human and animal 
sectors and increasing public awareness.11 
Tackling AMR will require the participation 
of staff in hospitals, clinics, pharmacies, 
veterinary hospitals and clinics, and live-
stock, fish, and arable farms to use antimi-
crobials appropriately, and to prevent and 
control infections. The plan has a clear long 
term focus to strengthen country capacity 
to reduce AMR guided by WHO’s joint exter-
nal evaluation tool for the International 
Health Regulations 2005.12
The strategies to achieve the goals of the 
national plan include:
•   Strengthen AMR surveillance using the 
One Health approach to cover humans, 
animals, and agriculture sectors and by 
disseminating information to prescribers 
and the public. This initiative will build 
on the existing national AMR surveil-
lance system and use measures from the 
global AMR surveillance system 14 devel-
oped by WHO for standardised AMR sur-
veillance
•   Regulate antimicrobial distribution by 
reclassification of certain antimicrobi-
als as prescription-only medicines and 
ensure effective law enforcement to con-
trol antimicrobial distribution
•   Prevent and control hospital acquired 
infections and improve antimicrobial 
stewardship to promote appropriate use 
of antimicrobials in hospitals, clinics, 
and pharmacies
•   Prevent and control the emergence and 
spread of resistant pathogens in live-
stock, fisheries, pets, and crops, and pro-
mote appropriate use of antimicrobials in 
livestock, aquaculture, and arable farms, 
and veterinary hospitals and clinics
•   Increase public awareness about AMR 
and promote the appropriate use of anti-
microbials
•   Establish a national governance mecha-
nism, such as a national committee on 
AMR policy and a national coordinating 
centre, to set policy, coordinate inter-
sectoral actions, monitor progress, and 
evaluate outcomes in order to implement 
and sustain AMR actions.
Box 3: Thailand’s contributions to the global agenda on AMR
•  As chair of the Group of 77 (G-77), the intergovernmental alliance of developing countries in 
the United Nations, Thailand supported the political declaration on AMR at the UN General 
Assembly in 2016 and called for solutions that would not affect access to antimicrobials 
•  One of 14 countries that established the Alliance of Champions at the WHO World Health 
Assembly in 2015 to promote political awareness, engagement, and leadership on AMR 
among heads of states, ministers, and global leaders 
•  One of seven countries in the Foreign Policy and Global Health Initiative that held a 
ministerial meeting in Oslo in 2014 to discuss ways to improve antimicrobial stewardship, 
with a focus on ensuring access for populations in low and middle income countries. After 
the meeting, Thailand was asked by the group to organise a ministerial side event on AMR at 
the 68th World Health Assembly
•  Lead country on the Global Health Security Agenda action packages for strengthening 
national laboratory systems and workforce development to tackle infectious disease threats, 
and contributed to the action package on AMR. Thailand hosted the Asia Pacific regional 
workshop in 2015 to develop country roadmaps and collaborations to build capacity in these 
areas 
•  Adopted the Jaipur Declaration on AMR in 2011, which is a commitment by member states 
of WHO’s South East Asia region to preserve the efficacy of antimicrobials and to adopt a 
multidisciplinary approach to prevention and containment of AMR 
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Programme monitoring
The Royal Thai Government and WHO 
country cooperation strategy programme 
on AMR will coordinate monitoring and 
evaluating the national plan, which has 
three parts.
•  Conduct mid and end term assessments 
of  outcomes  and  produce  publicly 
available reports every two years on AMR 
prevalence, antimicrobial consumption, 
and the status of public awareness
•  Strengthen the capacity of monitoring 
and evaluation systems as indicated in 
the WHO joint external evaluation tool
•  Generate  ev idence  for  ef fect ive 
implementation—for  example,  by 
identifying priority areas of research and 
engaging relevant stakeholders.
Way forward
Thailand’s strategic plan for antimicrobial 
resistance 2017-21 has just started and 
will require sustained and strong politi-
cal support. Guaranteed funding and the 
establishment of a permanent structure, 
such as the national coordinating centre 
on AMR to oversee implementation, are 
essential.
We  think  a main  requirement  is  to 
improve existing databases for monitoring 
antimicrobial consumption and reporting 
using  standardised measurements  in 
Box 4: Summary of the national strategic plan on antimicrobial resistance 2017-21
Vision: Reduction of mortality, morbidity,* and economic effects from AMR
Mission: Establish policies and national multisectoral mechanisms which support effective 
and sustained management of AMR
Goals:
•  50% reduction in AMR morbidity
•  20% reduction in antimicrobial consumption in humans
•  30% reduction in antimicrobial consumption in animals
•  20% increase in public knowledge of AMR and awareness of appropriate use of 
antimicrobials†
•  Increase in country capacity to tackle AMR to score 4 as measured by the WHO joint external 
evaluation tool‡
Strategies:
•  AMR surveillance system using the One Health approach
•  Regulation of antimicrobial distribution
•  Infection prevention and control and antimicrobial stewardship in humans
•  AMR prevention and control and antimicrobial stewardship in agriculture and pets
•  Increase in public awareness of AMR and appropriate use of antimicrobials
•  Governance mechanisms to implement and sustain AMR actions
 *AMR morbidity is defined as bacteraemia caused by five antibiotic resistant bacteria: Acinetobacter spp, Staphylococcus aureus, 
Escherichia coli, Klebsiella pneumoniae, and Pseudomonas spp
†A module on public knowledge of antimicrobial consumption and AMR awareness has been included in the 2017 Health 
and Welfare Survey, which includes 27 000 nationally representative households. The module is a modified version of the 
Eurobarometer 44513
 ‡Country capacity will be measured using the WHO joint external evaluation tool for International Health Regulations (2005).12 
The four key capacity areas (AMR detection, surveillance of infections caused by AMR pathogens, healthcare associated infection 
prevention and control programme, and antimicrobial stewardship activities for human and animal sectors) are given a 1 to 5 
score, where 1 = no capacity, 2 = limited capacity, 3 = developed capacity, 4 = demonstrated capacity, and 5 = sustained capacity
Stable or
  decreasing
  trends of
  AMR
Decreasing
  health, and
  economic
  burden
  related to
  AMR
Six strategies for tackling AMR Goals Ultimate
outcomes
50% reduction of
AMR morbidity
Strategy 6
Governance mechanisms
to implement and
sustain AMR actions
Note: strategy 6 facilitates,
and harmonises strategies
1-5 implementation.
It also connects with
Royal Thai Government and
WHO Country Cooperation
Programme for evaluation
of NSP-AMR, and research
and development to enhance
eective implementation
of strategic plan
20% reduction
of antimicrobial
consumption in humans
30% reduction
of antimicrobial
use in animals
20% increase in public
awareness on AMR
and antimicrobial use
Country capacity
addressing AMR
achieves score 4
of JEE tool
Strategy 1
AMR surveillance using One Health approach
Strategy 2
Regulation of antimicrobial distribution
Strategy 3
Infection prevention and control, and
antimicrobial stewardship
Strategy 5
Public awareness on AMR, and appropriate
use of antimicrobials
Royal Thai Government (RTG)-WHO Country Cooperation Strategy programme on AMR (CCS-AMR Programme)
Area of work 1 Monitoring and evaluation (M&E) of NSP-AMR implementation by generating mid term and end term report of
  NSP-AMR implementation and publicly available biennial report on AMR prevalence, antimicrobial consumption, and public
  awareness
Area of work 2 Strengthen capacity of M&E systems to monitor AMR morbidity and mortality, antimicrobial consumption,
  public awareness, and country capacity to address AMR problems as indicated in joint external evaluation tool
Area of work 3 Building capacity for evidence generation including mapping expertise, research gaps, priority setting for
  research, training etc
Strategy 4
AMR containment, and antimicrobial use in
agriculture and animals
Fig 1 | Framework of the implementation and evaluation of the national strategic plan on antimicrobial resistance (NSP-AMR). Modified 
from the Royal Thai Government and WHO country cooperation strategy programme on AMR (2017-21) 
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humans and animals.  Interoperability 
between hospital discharge  summary 
and civil registration systems needs to be 
improved for a reliable estimation of AMR 
morbidity and mortality.
AMR is a component of other national 
policies (box 5). Support is needed to 
improve  individual and  institutional 
capacities and collaboration between 
di f ferent   sectors   to   tackle   AMR. 
Multisectoral  action  is  complex  as 
stakeholders have their own interests 
and expectations, but  the process of 
producing the strategic plan has helped 
develop a shared vision.  Information 
sharing,  understanding  the  roles  of 
different stakeholders, and engaging 
in   jo int   pro jec ts   wi l l   encourage 
collaboration towards a common view 
on AMR.
Thailand has demonstrated commitment 
to tackle AMR for many years despite the 
absence of a national action plan. The 
strategic plan provides a platform for cross-
sectoral coordination through a shared 
vision and has a strong foundation because 
of  the  engagement  and  ownership  of 
relevant stakeholders. Sustained political 
commitment is essential for the effective 
implementation of policies and monitoring 
in the long run.
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